Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure.
about
Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinolRole of Oxidative Stress in Thyroid Hormone-Induced Cardiomyocyte Hypertrophy and Associated Cardiac Dysfunction: An Undisclosed StoryXanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications.Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data.Xanthine oxidase inhibition preserves left ventricular systolic but not diastolic function in cardiac volume overload.Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trialElectrophysiological remodeling in human atrial fibrillation.Apoptosis and heart failure: mechanisms and therapeutic implications.Reactive oxygen species and autonomic regulation of cardiac excitability.Role of xanthine oxidoreductase in cardiac nitroso-redox imbalanceXanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in miceβ3-Adrenergic receptor antagonist improves exercise performance in pacing-induced heart failureUric acid and inflammatory markersNeuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction couplingXanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta-analysis.Monoamine oxidase is a major determinant of redox balance in human atrial myocardium and is associated with postoperative atrial fibrillation.Effect of acute xanthine oxidase inhibition on myocardial energetics during basal and very high cardiac workstatesXanthine oxidoreductase: a journey from purine metabolism to cardiovascular excitation-contraction coupling.Physiological regulation of cardiac contractility by endogenous reactive oxygen species.Uric acid in heart failure: a biomarker or therapeutic target?Posttranslational modifications of cardiac ryanodine receptors: Ca(2+) signaling and EC-coupling.Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure?Redox modulation of the inotropic response to dobutamine is impaired in patients with heart failure.Binding of xanthine oxidase to glycosaminoglycans limits inhibition by oxypurinol.Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure.Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III - IV congestive heart failure.Chronic xanthine oxidase inhibition prevents myofibrillar protein oxidation and preserves cardiac function in a transgenic mouse model of cardiomyopathy.Effect of vitamin C and L-NMMA on the inotropic response to dobutamine in patients with heart failure.Age-related increase in xanthine oxidase activity in human plasma and rat tissues.Twinkle overexpression prevents cardiac rupture after myocardial infarction by alleviating impaired mitochondrial biogenesis.Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure.Multiple evidence for an early age pro-oxidant state in Down Syndrome patients
P2860
Q24652967-43D5580A-3404-4060-8BF9-C81084112A2CQ28648268-9CC4FAEE-89D8-4F34-A182-578E53DAFEEFQ30336517-2AA139BE-7F16-433F-B873-070E7265B99BQ33784030-2644717E-289A-43A2-86BB-BD0A22536798Q33816822-70DF459D-A460-494B-A860-555C43FC95B3Q33935192-B7B754F3-F698-4705-AE1B-9A59FA878ECFQ35197739-2E6F9551-F92C-49D3-B8F3-A8B2D0F6210AQ35631256-4705DEFB-4C15-42B7-B99B-F926A9E1C81FQ36474121-B9A4BF8D-84BD-48A3-9BB8-5DD45C9089DAQ36557850-590D5A46-23FA-4D15-A0EB-C329B5A3BD78Q37029569-23AEF309-AC44-431F-927E-A3B1331A61D4Q37142802-608F8154-EE03-4DB1-8FCD-E22E732BAED5Q37156498-472E4857-4F8F-4C47-8E23-5256DDB47701Q37619331-5CFC637F-E6E1-4721-9C1C-E6BB1A80D418Q37625569-A9FBCE04-9CB8-49B7-87EC-0FEB48C3AA61Q37648518-DFE88D18-54A4-4334-A918-13DFBB5C40E1Q37662353-5ED8B43A-C586-46B4-A372-D2A0ED8FBFD3Q37903030-2807D7C5-50B0-466A-B713-00890368214FQ37998560-26D1A18F-74FC-40B2-972C-D0EF29608997Q38010013-1E7116A5-ABF1-48A2-94AC-60AE4BF8060DQ38041916-187C5C29-CF14-4638-BA89-A3987C1C28F0Q43012542-0CA53817-E06E-4765-94A5-D52D8C0C10BBQ44612941-160AFAFA-053E-41E0-AB53-0ADE1EF24996Q44962055-38895CC8-915E-42EF-8F4E-F281809698E8Q45108007-2C5EC7F4-61CC-4ABA-93E3-141F40DC72BEQ45120611-19371D60-1166-441C-AE98-48C08559995CQ46465722-CBFCE003-A511-4689-BF77-B0B6753CF500Q46616122-CF434B81-27B5-405A-A48C-CF931CB0E6FAQ46973591-AE7F75F9-BB08-4EEA-BAF1-7FB410206F4DQ51682521-D5AD5F6F-1417-471D-8D17-3A024AC35855Q55663138-DBC33484-2F7B-408C-8771-6CD66D6B2704Q56601690-FE34B7F9-23AF-4676-8A2D-C92DDB44D39D
P2860
Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Allopurinol enhances the contr ...... pacing-induced heart failure.
@ast
Allopurinol enhances the contr ...... pacing-induced heart failure.
@en
type
label
Allopurinol enhances the contr ...... pacing-induced heart failure.
@ast
Allopurinol enhances the contr ...... pacing-induced heart failure.
@en
prefLabel
Allopurinol enhances the contr ...... pacing-induced heart failure.
@ast
Allopurinol enhances the contr ...... pacing-induced heart failure.
@en
P2093
P356
P1433
P1476
Allopurinol enhances the contr ...... pacing-induced heart failure.
@en
P2093
Tachibana H
P304
P356
10.1161/01.CIR.103.5.750
P407
P577
2001-02-01T00:00:00Z